Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced the pricing of an underwritten public offering of 7,608,696 primary shares of its common stock at a public offering price of $4.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $35 million. The offering is expected to close on or about February 26, 2014, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,141,304 additional shares of common stock. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock opened at $4.81 in last session, and closed at $4.61, while the day range of PGNX stock is $4.60-$4.97.The stock showed a negative weekly performance of -5.73%.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was downgraded by equities research analysts at Ladenburg Thalmann from a “buy” rating to a “neutral” rating in a research. They currently have a $15.50 price objective on the stock. Ladenburg Thalmann’s price objective would suggest a potential downside of 9.57% from the company’s current price Raptor Pharmaceutical Corp. (NASDAQ:RPTP) stock opened at $16.42, in last session and closed at $16.18, by loosed -5.60%.The 52 week range was $4.92-$17.72.Company’s market capitalization is $991.70 million.
Dehaier Medical Systems Ltd (NASDAQ:DHRM) sank 14.98% early Friday after news that it has signed a securities purchase agreement with certain institutional investors for the sale of 737,700 common shares in a registered offering at the price of $9.12 per common share. After payment of expenses, the company expects to receive net proceeds of approximately $6.1 million. Furthermore, the investors will be issued warrants to purchase 220,410 common shares in the aggregate. The company said if fully exercised, it would receive aggregate gross proceeds from the warrants of approximately $2.6 million. Dehaier Medical Systems Ltd (NASDAQ:DHRM) stock loosed -14.73% and finished the last session at $10.19.The EPS of the stock remained 0.63.Company’s market capitalization is $47.08 million.
The ThermoGenesis Corp (NASDAQ:KOOL) on Feb. 14 reported financial results for the second quarter of fiscal 2014. For the quarter ended December 31, 2013, revenues were $4.5 million, compared to $4.8 million for the same period in 2012. Net loss for the quarter ended December 31, 2013 was $1.6 million or $0.10 per share, compared to $563 thousand or $0.03 per share for the same prior year period. ThermoGenesis Corp (NASDAQ:KOOL) stock opened the session at $2.55, and closed the session at $2.40. The 52 week range of the KOOL stock remained $0.71-$3.24 and the day range was $2.30-$2.61.